Overview

SGA-induced Metabolic Syndrome in Bipolar Youth

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
The investigators will test the hypothesis that the adverse effects of second-generation antipsychotics exposure and the beneficial effects of long-chain omega-3 (LCn-3) fatty acids are mediated by opposing effects on the enzyme implicated in the metabolic syndrome and obesity.
Phase:
Phase 3
Details
Lead Sponsor:
University of Cincinnati
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Quetiapine Fumarate